Richard C. Zellars, MD
Assistant Director for Clinical Trials Accrual
Associate Professor, Department of Radiation Oncology and
Molecular Radiation Sciences
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
2013-2014 BCRF Project:
(The Pink Agenda Award)
In contrast to Dr. Zellars’s partial breast irradiation (PBI) and concurrent chemotherapy studies, other PBI trials had higher rates of local recurrence in women with triple negative and estrogen receptor (ER) negative breast tumors. Consequently to determine benefit of PBI and concurrent chemotherapy with respect to local control in this population, Dr. Zellars designed a randomized trial of PBI with concurrent vs. sequential chemotherapy in women with ER- breast cancer. Also his team wishes to continue enrolling patients in their trial of pre-operative PARP inhibitor and radiation in women with residual disease after neoadjuvant chemotherapy. The combination of radiation (which causes DNA breaks) and PARP inhibitor (which prevents repair of the DNA breaks) should result in great cancer cell kill than either agent alone.
Dr. Zellars is a graduate of the Johns Hopkins School of Medicine. He completed his residency at the University of Michigan in the Department of Radiation Oncology, where he was Chief Resident from 1995-96. He next accepted an appointment as an Assistant Professor of Radiation Oncology at the University of Texas Health Science Center in San Antonio. During his tenure there, Dr. Zellars also served as Clinic Director and Vice Chair. Before returning to Johns Hopkins and the Sidney Kimmel Comprehensive Cancer Center, he was at Georgetown University Department of Radiation Medicine. Currently, Dr. Zellars is Associate Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at Hopkins. In January 2013, Dr. Zellars was appointed Assistant Director for Clinical Trials Accrual at the Sidney Kimmel Comprehensive Cancer Center, where he will focus on the recruitment of minority patients to clinical trials.
Dr. Zellars's primary research interests are the evaluation of putative prognostic factors for local failure and the development of new radiation therapy techniques, all with respect to breast cancer.